Your session is about to expire
← Back to Search
Tanimilast Add-On Therapy for Chronic Obstructive Pulmonary Disease (PILASTER Trial)
PILASTER Trial Summary
This trial will test if a medication helps and is safe for people with a certain type of lung disease.
PILASTER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPILASTER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PILASTER Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants being sought for this medical experiment?
"Clinicialtrials.gov indicates that this clinical study is actively enrolling patients; the trial was first advertised on July 14th 2021 and recently revisited on October 2nd 2023."
Could you please provide a summary of prior research examining the impacts of CHF6001 1600µg?
"At the present time, there are two clinical trials investigating CHF6001 1600µg in Phase 3. Although Haskovo, Alabama is a site of many studies for this medication, it can be obtained from 848 different locations across the world."
Does the FDA recognize CHF6001 1600µg as safe for human consumption?
"CHF6001 1600µg has been assessed as a 3 on the safety scale, which is based off of its Phase 3 status and associated data indicating efficacy and multiple rounds of testing confirming safety."
Are there any medical establishments in this city conducting the trial?
"This trial is enlisting patients from various sites, including Miami, Peachtree Corners and New Windsor. Additionally, it has 382 other locations across the nation. To reduce travel demands when enrolling in this study, we recommend picking a site closest to you."
Does this clinical research represent a pioneering breakthrough in its field?
"Currently, 82 cities and 34 nations host 2 ongoing CHF6001 1600µg investigations. Initially commencing in 2021, the trial funded by Chiesi Farmaceutici S.p.A., encompassed 3980 participants during its Phase 3 evaluation process. Since then, 19496 trials have been conducted."
What is the uppermost participant limit for this medical experiment?
"The trial sponsor, Chiesi Farmaceutici S.p.A., requires a total of 3435 eligible participants to conduct the study across two locations: 100423 - Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases in Miami, Georgia and Chiesi Clinical Trial - Site 840437 in Peachtree Corners, New york."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger